Skip to contentV
Voyager Therapeutics, Inc.
V
VYGRVoyager Therapeutics, Inc. Q3 2017 · 10-Q
Revenue$1.15M$1.15M−65.3% vs Q3 2016 Net Income-$23.35M-$23.35MN/M vs Q3 2016 EPS Diluted-$0.89-$0.89N/M vs Q3 2016 Operating Income-$23,355,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Voyager Therapeutics, Inc. · CIK 1640266 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$16,299,000N/M Margins · derivedOperating margin-2034.4%−1720.9 pt vs Q3 2016
Net margin-2033.6%−1761.7 pt vs Q3 2016
ended Sep 30, 2017 · filed Nov 2, 2017 · 33 d after period end